(MedPage Today) — At the recent American Society of Clinical Oncology (ASCO) meeting, early data from the DREAMM-20 trial showed that the naked B-cell maturation antigen (BCMA)-targeted monoclonal antibody belantamab — without the cytotoxic…
Source link : https://www.medpagetoday.com/meetingcoverage/ascofuturefocusmm/116340
Author :
Publish date : 2025-07-01 19:15:00
Copyright for syndicated content belongs to the linked Source.
